Affiliation: Merck Research Laboratories
- A double-blind, dose-response study of losartan in hypertensive childrenShahnaz Shahinfar
Merck Research Laboratories, West Point, Pennsylvania, USA
Am J Hypertens 18:183-90. 2005..The aim of this study was to determine the dose-response relationship for losartan, 2.5 to 100 mg, and to assess the safety and tolerability of losartan in hypertensive children 6 to 16 years of age...
- Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec
Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
Diabetes Care 31:445-7. 2008..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
- A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild tGilbert W Gleim
Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
Clin Ther 28:1639-48. 2006..Because patients with hypertension may require >1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications...
- A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertensionBeth Soffer
Merck and Co, Inc, West Point, Pennsylvania, USA
Am J Hypertens 16:795-800. 2003..Despite widespread use in hypertensive children, the safety and effectiveness of lisinopril had not been previously tested in a controlled study...
- Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang
Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
J Am Soc Nephrol 16:1775-80. 2005....
- Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Clin J Am Soc Nephrol 1:761-7. 2006..Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors...
- The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane
Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA
Kidney Int 63:1499-507. 2003..We examined the risk factors that predict loss of kidney function (doubling of serum creatinine) or ESRD (dialysis or transplantation) in patients with type 2 diabetes in whom blood pressure was controlled...
- The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides
Merck and Co Inc, Blue Bell, Pennsylvania 19422, USA
Pharmacoeconomics 24:549-58. 2006..4 years). The objective of this study was to project the effect of losartan compared with placebo on the lifetime incidence of ESRD and associated costs (from a US healthcare system perspective)...
- Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairmentTania Z Dickson
Merck and Co, Inc, P O Box 4, BLX 21, West Point, PA 19486, USA
J Clin Pharmacol 43:591-603. 2003..Overall, the combination of losartan/hydrochlorothiazide was effective in lowering blood pressure and was well tolerated in patients with mild to moderate renal impairment...
- Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr
Circulatory Disease Center, Augusta, Georgia, USA
Am J Cardiol 96:1530-6. 2005..The beneficial effect of losartan on the reduction of risk for hospitalization for new HF was demonstrated in patients who were at high renal and/or high cardiovascular risk...
- Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Expert Opin Pharmacother 7:623-30. 2006..The RENAAL study also provided information that will be valuable to those designing future clinical trials in this patient population. This review highlights key findings from the RENAAL study...
- Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetesWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
Diabetes Care 29:2210-7. 2006....
- Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL studyKiyoshi Kurokawa
Research Center for Advanced Science and Technology of the University of Tokyo, 4 6 1 Komaba, Meguro ku, Tokyo, 153 8904, Japan, and The Prince of Wales Hospital, Hong Kong, China
Clin Exp Nephrol 10:193-200. 2006..The original study of 1513 patients included 96 Japanese patients; the present study is a post-hoc analysis of the effects of losartan in this Japanese subpopulation...
- A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertensionRonald J Hogg
St Joseph s Hospital and Medical Center, 222 W Thomas Rd, Suite 410, Phoenix, AZ 85013, USA
Pediatr Nephrol 22:695-701. 2007..h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported...
- Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp
Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
J Hypertens 25:871-6. 2007....
- Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp
Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
J Am Soc Nephrol 18:1540-6. 2007..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
- Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey
Main Line Health Heart Center, Wynnewood, Philadelphia, USA
Clin Cardiol 28:136-42. 2005..Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions...
- A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertensionThomas Wells
University of Arkansas for Medical Sciences and Arkansas Children s Hospital, Little Rock 72202, USA
J Clin Pharmacol 42:870-80. 2002..08 mg/kg) administered once daily effectively lowered blood pressure within 2 weeks in most patients. Blood pressure was reduced in a dose-dependent fashion, with larger doses resulting in a greater reduction...
- Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman
Departments of Internal Medicine and Epidemiology, University of Michigan Health System, Ann Arbor, Michigan 48109 0354, USA
Diabetes Care 26:683-7. 2003..To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD)...
- Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Diabetes Care 26:1402-7. 2003....
- Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysisTazeen H Jafar
Tufts New England Medical Center, Boston, Massachusetts 02111, USA
Ann Intern Med 139:244-52. 2003..Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chronic kidney disease...
- The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysisTazeen H Jafar
New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
Nephrol Dial Transplant 18:2047-53. 2003..Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender...
- Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan
Department of Medicine and Therapeutics, The Chinese University Hong Kong, The Prince of Wales Hospital, Hong Kong, Shatin, China
Diabetes Care 27:874-9. 2004..In this subgroup analysis, we examined the characteristics, response, and adherence to treatment of the Asian population, as well as their baseline predictors of risk of renal end points...
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALDick de Zeeuw
Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
Kidney Int 65:2309-20. 2004....
- The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathyWilson Y S Leung
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, N T, Hong Kong, SAR
Nephrol Dial Transplant 19:2519-25. 2004..In this subgroup analysis from the RENAAL Study, we hypothesized that the intensive care received by patients in a clinical trial setting also reduced the rate of decline in renal function through optimization of all risk factors...
- Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw
Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
Circulation 110:921-7. 2004..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
- Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathyAnupama Mohanram
UT Southwestern Medical Center, Dallas, Texas 75390 8856, USA
Kidney Int 66:1131-8. 2004..Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined...
- Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi
Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
J Am Soc Nephrol 15:3117-25. 2004..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
- ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans Henrik Parving
Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
J Am Soc Nephrol 19:771-9. 2008..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
- Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas
The Baker Medical Research Institute, Victoria, Australia
Kidney Int 63:1577-9. 2003